163 related articles for article (PubMed ID: 15559526)
21. Discontinuation of Vioxx.
Kim PS; Reicin AS
Lancet; 2005 Jan 1-7; 365(9453):23; author reply 26-7. PubMed ID: 15639669
[No Abstract] [Full Text] [Related]
22. Merck withdraws Vioxx; FDA issues public health advisory.
FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
[No Abstract] [Full Text] [Related]
23. [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
Brune K; Zacher J
MMW Fortschr Med; 2004 Oct; 146(42):10, 12. PubMed ID: 15536697
[No Abstract] [Full Text] [Related]
24. How to avoid another 'Vioxx'.
Frantz S
Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
[No Abstract] [Full Text] [Related]
25. The Vioxx debacle revisited.
Good CB; Kelley CL
Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902
[No Abstract] [Full Text] [Related]
26. [80,000 patients with arthrosis treated. Coxib gets through a practice test, too].
MMW Fortschr Med; 2002 Oct; 144(41):60. PubMed ID: 12474372
[No Abstract] [Full Text] [Related]
27. [Analgesic in osteoporosis. Why so conservative with dosage?].
Pfeifer M
MMW Fortschr Med; 2002 Sep; 144(35-36):9. PubMed ID: 12380349
[No Abstract] [Full Text] [Related]
28. Discontinuation of Vioxx.
Garattini S; Bertelé V
Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
[No Abstract] [Full Text] [Related]
29. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
Mühlbauer B; Timm J
Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
[No Abstract] [Full Text] [Related]
30. Increased risk of cardiovascular events with coxibs and NSAIDs.
Scott DG; Watts RA
Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299
[No Abstract] [Full Text] [Related]
31. Matters of the heart: assessing the cardiovascular safety of new drugs.
Konstam MA
Am Heart J; 2003 Oct; 146(4):561-2. PubMed ID: 14564304
[No Abstract] [Full Text] [Related]
32. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
33. Vioxx, the implosion of Merck, and aftershocks at the FDA.
Horton R
Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
[No Abstract] [Full Text] [Related]
34. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Jugdutt BI
Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292
[No Abstract] [Full Text] [Related]
35. [Therapy with rofecoxib. Decreasing risk by controlled COX-2 inhibitor administration].
MMW Fortschr Med; 2000 Nov; 142(48):64-5. PubMed ID: 11144940
[No Abstract] [Full Text] [Related]
36. Balancing the cyclooxygenase portfolio.
Armstrong PW
CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
[No Abstract] [Full Text] [Related]
37. [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].
Kick A; Bertoli R; Moschovitis G; Caduff Janosa P; Cerny A
Med Klin (Munich); 2005 Apr; 100(4):213-6. PubMed ID: 15834531
[TBL] [Abstract][Full Text] [Related]
38. Rofecoxib does not adversely affect skin graft survival in a rat model.
Miller Q; Losken A; Harre JG; Bird ME
Curr Surg; 2004; 61(2):227-30. PubMed ID: 15051270
[No Abstract] [Full Text] [Related]
39. Lessons on prescribing and drug safety from the withdrawal of rofecoxib.
Nelson M; Cicuttini F
Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913
[No Abstract] [Full Text] [Related]
40. Painful lessons.
Nat Struct Mol Biol; 2005 Mar; 12(3):205. PubMed ID: 15744317
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
